Analyst Report ) recently announced that it has received accelerated approval from the U.S. Food and Drug Administration for the use of Tykerb as a first-line treatment for women with metastatic breast cancer in a new combination regimen.

The U.S. Food and Drug Administration has expanded approval for Tyberb to include postmenopausal women with hormone- and HER2-positive advanced breast cancer who require hormone therapy.

Postmenopausal women who have been diagnosed with HER2 positive , estrogen receptor sensitive breast cancer can now take advantage of a drug combination just approved by the FDA.

GlaxoSmithKline's breast cancer drug Tykerb can now be used in combination with the Novartis cancer drug Femara, the U.S. Food and Drug Administration says.

Provides oral regime for hormone positive and HER2-positive advanced breast cancer - The U.S. Food and Drug Administration approved Tykerb in combination with Femara to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

TYKERB is now indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application to market its generic version of Novartis' breast cancer treatment Femara Tablets, 2.5 mg.

JERUSALEM The Food and Drug Administration has given tentative approval to Teva Pharmaceutical Industries for its generic version of a breast cancer treatment, the Israeli drug maker announced Thursday.

Editor's Choice Main Category: Breast Cancer Article Date: 24 Dec 2009 - 0:00 PST The aromatase inhibitor letrozole produces a significant survival benefit over tamoxifen when used as adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer , according to updated results of a major trial released in a plenary session at the ...

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

A HEALTHCARE assistant was spurred into action to improve the supply of cancer fighting drugs after a breast cancer patient was unable to get her prescription.

Hormone therapy is a treatment option for women with early-stage, hormone-sensitive breast cancer, identified by the presence of hormone receptors.

Main Category: Breast Cancer Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 20 Aug 2009 - 2:00 PDT Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara ) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with ...

For postmenopausal women with breast cancer, treatment with the drug letrozole increases survival after surgery more than the widely used tamoxifen, a new study confirms.

For postmenopausal women with breast cancer, treatment with the drug letrozole increases survival after surgery more than the widely used tamoxifen, a new study confirms.